Clinical Trials Directory

Trials / Unknown

UnknownNCT04311398

Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Huashan Hospital · Academic / Other
Sex
All
Age
16 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Our project intends to independently develop a fully enclosed rapid detection system for a total of 22 pathogens, including SARS-CoV-2, on the basis of the QIAstat-Dx fully automatic multiple PCR detection platform. The reasonably designed experiments are used to verify the performance of the cartridge detection and prove its clinical application value. The 22 pathogens tested in this project includes 4 coronavirus subtypes, A / B flu, parainfluenza virus, respiratory syncytial virus, etc., which is of great significance for the differential diagnosis of similar patients.

Detailed description

COVID-19 has not been well suppressed, and became a pandemic within 3 months globally is mainly because of the virus characteristic in the following aspects: 1. Long incubation period (average 5-7 days, up to 28 days), and the incubation period is contagious 2. Strong transmissibility, virus can be transmitted through aerosol 3. Difficulty distinguishing infected patients from other pathogenic infections 4. High negative rate of nucleic acid detection in upper respiratory tract samples of infected patients, which increases the difficulty of differential diagnosis of infection with other pathogens The existing RT-PCR nucleic acid detection kits for SARS-CoV-2 has two major problems. First, the procedure is not automated leading to higher requirements for personnel operation level and environment sterilize. What's more the kits are SARS-CoV-2 only. Once the test result is negative, it cannot help diagnose the exact pathogen in one time of experiment. Therefore, this project intends to independently develop a fully enclosed rapid detection system for a total of 22 pathogens, including SARS-CoV-2, on the basis of the QIAstat-Dx fully automatic multiple PCR detection platform. The reasonably designed experiments are used to verify the performance of the cartridge detection and prove its clinical application value. The 22 pathogens tested in this project includes 4 coronavirus subtypes, A / B flu, parainfluenza virus, respiratory syncytial virus, etc., which is of great significance for the differential diagnosis of similar patients.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTNew QIAstat-Dx fully automatic multiple PCR detection platformWe use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients

Timeline

Start date
2020-05-13
Primary completion
2020-06-01
Completion
2020-12-01
First posted
2020-03-17
Last updated
2020-05-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04311398. Inclusion in this directory is not an endorsement.